Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer [PDF]
Frontiers in Pharmacology, 2023 Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair.
Ruihong Dong +5 more
doaj +2 more sources
Poly (ADP-ribose) polymerase inhibitors in cancer therapy [PDF]
Chinese Medical Journal. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death ...
Ziqi Zhu, Yujun Shi, Jing Ni
doaj +2 more sources
Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress [PDF]
Redox Biology, 2014 Oxidative stress can cause DNA breaks which induce activation of the DNA nick sensor enzyme poly(ADP-ribose) polymerase-1 (PARP-1), part of the 17 member PARP enzyme family.
Csaba Hegedűs, László Virág
doaj +3 more sources
Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors [PDF]
Reviews in Cardiovascular MedicineThe Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including ...
Jie Ma +8 more
doaj +2 more sources
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
Women's Health, 2018 There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and ...
Maurie Markman
doaj +2 more sources
R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP–Ribose) Polymerase Inhibitors [PDF]
Bioinformatics and Biology InsightsAn advanced graph neural network (GNN) is of great promise to facilitate predicting Poly ADPribose polymerase inhibitors (PARPi). Recent studies design models by leveraging graph representations and molecular descriptor representations, unfortunately ...
Candra Zonyfar +3 more
doaj +2 more sources
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy [PDF]
Frontiers in Chemistry, 2020 A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged ...
Bijay Singh +10 more
doaj +2 more sources
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
Therapeutic Advances in Medical Oncology, 2011 The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi).
M. Javle, N. J. Curtin
doaj +2 more sources
Poly(ADP-ribose)polymerase activity controls plant growth by promoting leaf cell number [PDF]
, 2014 A changing global environment, rising population and increasing demand for biofuels are challenging agriculture and creating a need for technologies to increase biomass production.
Claeys, Hannes +8 more
core +12 more sources
Journal of Medical Case Reports, 2021 Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer.
Rosa Montero-Macias +12 more
doaj +1 more source